Associations of Vitamin D Deficiency and Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma

Overview

This study investigated whether vitamin D receptor gene polymorphism is altered in primary open-angle glaucoma subjects carrying the risk allele and vitamin D deficiency is an important factor in the development of glaucoma. Primary open-angle glaucoma patients and age-matched people in the Han population were enrolled. Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay. Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2014

Interventions

  • Other: Vitamin D receptor polymorphic analysis
    • Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
  • Other: Serum levels of 1a, 25-Dihydroxyvitamin D3
    • Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.

Arms, Groups and Cohorts

  • primary open-angle glaucoma patients
    • Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
  • randomly age-matched people
    • Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.

Clinical Trial Outcome Measures

Primary Measures

  • Serum levels of 1a, 25-Dihydroxyvitamin D3
    • Time Frame: 1 day visit

Secondary Measures

  • gene polymorphisms of vitamin D receptor
    • Time Frame: 1 day visit

Participating in This Clinical Trial

Inclusion Criteria

  • intraocular pressure greater than 22 mmHg with two or more medications
  • wide anterior chamber angle
  • glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect)
  • visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry

Exclusion Criteria

  • the presence of any secondary glaucoma including exfoliation syndrome or a history of ocular trauma
  • high myopia
  • macular degeneration
  • other ocular diseases
  • a known history of systemic diseases and administration of vitamin D3 or other analog

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Lv Yingjuan
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Lv Yingjuan, department of ophthamology – Tianjin Medical University Eye Hospital
  • Overall Official(s)
    • xiaorong li, Study Director, Tianjin Medical University Eye Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.